TREATMENT OF ANTIBODY DEFICIENCY
Prospective clinical studies have shown that optimal IgG replacement therapy reduces the incidence of sepsis and complications like structural lung damage. If replacement therapy is introduced early before organ damage is established, antibody-deficient individuals are likely to have a normal life span. Replacement immunoglobulin is prepared from plasma pooled from large cohorts of normal donors. Current practice of prescreening donors for infection and multiple antiviral steps employed during the manufacture of plasma have eliminated the risk of HIV and hepatitis B and C transmission. Different immunoglobulin products are licensed for administration via the intravenous or subcutaneous route.